IBJNews

Marcadia may fetch up to $537 million in sale

Back to TopCommentsE-mailPrintBookmark and Share

The December sale of Carmel-based Marcadia Biotech to Roche garnered at least $287 million for the company’s owners and could lead the Marcadia team to launch a firm using one of Marcadia’s experimental diabetes medicines.

New details about the deal were released Wednesday by Switzerland-based Roche, a massive pharmaceutical and diagnostic firm, which operates its North American diagnostic business out of Indianapolis. Marcadia’s investors could get an extra $250 million—on top of the $287 million in upfront cash—from Roche as its experimental drugs move closer and closer to market.

The sale was a “home run” for Marcadia’s investors, said Fritz French, who until Monday was Marcadia’s CEO. Before leading the company, French had been vice president for global marketing for a division of Guidant Corp.

Since its founding in 2006, Marcadia had attracted $16 million in venture capital, most of it in a 2007 infusion from California-based 5AM Ventures and Seattle-based Frazier Healthcare. But more recently, Marcadia had funded its drug development through deals with New Jersey-based Merck & Co. Inc. and Indianapolis-based Eli Lilly and Co.

Those streams of revenue meant Marcadia didn’t have to sell, French said. But still, he and his management team started meeting with executives at other pharmaceutical firms about a year ago at the JP Morgan Health Care conference in San Francisco.

“Things just kind of developed with a number of companies,” French said. “Roche was the best bet from a lot factors, including financially.”

Marcadia was trying to develop numerous experimental diabetes medicines, based on research conducted at Indiana University in the labs of Richard DiMarchi, a former vice president of Lilly Research Laboratories in Indianapolis.

Under the sale to Roche, French said, IU will retain ownership of the drugs Marcadia was developing, but the licensing rights will shift to Roche.

French and most of the 11 employees at Marcadia now want to license from Roche a glucagon compound that Marcadia was developing with Lilly for patients with hypoglycemia. If his negotiations with Roche are successful, the former Marcadia team would form a new company to try to bring that compound to market.

Lilly already sells a glucagon drug, but its sales are less than $80 million a year. There are also other glucagons sold by Denmark-based Novo Nordisk A/S and other competitors, but they do not have huge sales levels.

French thinks that’s because they’re inconvenient. Lilly’s current glucagon product comes in a powder that must be mixed up with water and placed in a syringe before injection. But Marcadia was trying to develop a short-acting glucagon that could be stored as a solution in an injection “pen,” ready for immediate use during an episode of extremely low blood sugar.

The compound, known as MAR 531, is soon to start clinical trials.

The Marcadia management team, in addition to French and DiMarchi, included Jaswant Gidda, a former senior research adviser at Lilly; Kent Hawryluk, a former partner at Indianapolis-based Twilight Venture Partners; Ralph Riggin, a former research adviser at Lilly; Kristin Sherman, a former treasurer of Guidant; and Dr. Skip Vignati, a former medical director of endocrine research at Lilly.

“There’s a pretty rich pool of people that are here that want to stay in Indiana,” French said. “I hope this is just one of many more successes.”

ADVERTISEMENT

  • Congratulations
    Hi Ruth & Skip,
    Very nice success. Way to go Skip.
    John Bradburn

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Only half a million TV Viewers? And thats an increase? I knew Indycar was struggling but I didn't know it was that bad. Hell, if NASCAR hits 5 Million viewers everyone starts freaking out saying its going down hill. It has a long way to before Indycar even hits NASCAR's bad days.

  2. IU has been talking that line for years with no real progress even with the last Dean, Dr. Brater. Why will an outsider, Dr. Hess, make a difference? With no proof of additional resources (cash in the bank), and a concrete plan to move an academic model that has been outdated for decades with a faculty complacent with tenure and inertia, I can count on IU to remain the same during the tenure of Dr. Hess. One ought to look to Purdue and Notre Dame for change and innovation. It is just too bad that both of those schools do not have their own medical school. Competition might wake up IU. My guess is, that even with those additions to our State, IU will remain in its own little world squandering our State's tax dollars. Why would any donor want to contribute to IU with its track record? What is its strategy to deal with the physician shortage for our State? New leadership will not be enough for us to expect any change.

  3. How do you think the Bridges got approved? I spent a couple days researching PAC's and individual contributions to some city council members during that time. My printouts were inches thick on the two I concentrated on. Finally gave up. Was disgusted with all the donations, and who they were from. Would have taken me days and days to compile a complete list. Tried to give it to the Star reporter, but he thought it was all just fine. (and apparently he was treated well himself) He ended up being laid off or fired though. And then of course, there was land donated to the dad's club, or city, as a partial payoff. All done in the shining example of "charity." No, none of these contributions are a coincidence.

  4. I agree what kind of help or if any will be there for Dr. Ley's patients. I was a patient myself.

  5. What about the hundreds of patients who sought this doctor for the right reasons, to quit drugs. what option do these patients now have, experience horrible withdrawl or return to heroin?? those are the choices. what about the children of these former addicts who's parent(s) WILL not b able to maintain their job, for @ least 2 weeks.. There needs to b an emergency clinic opened for these patients.

ADVERTISEMENT